Skip to main content

Articles

Page 4 of 4

  1. OP03 Selective extraction of medically-related radionuclides from proton-irradiated thorium targets

    Authors: V. Radchenko, J. W. Engle, C. Roy, J. Griswold, M. F. Nortier, E. R. Birnbaum, M. Brugh, S. Mirzadeh, K. D. John, M. E. Fassbender, Chuangyan Zhai, Gerben M. Franssen, Milos Petrik, Peter Laverman, Clemens Decristoforo, Ait-Mohand Samia…
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1(Suppl 1):10

    This article is part of a Supplement: Volume 1 Supplement 1

  2. Traditional nuclear medicine ligands were designed to target cellular receptors or transporters with a binding pocket and a defined structure–activity relationship. More recently, tracers have been developed t...

    Authors: Aleksandar Jovalekic, Norman Koglin, Andre Mueller and Andrew W. Stephens
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:11

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  3. 213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide therap...

    Authors: Ho Sze Chan, Erik de Blois, Mark W. Konijnenberg, Alfred Morgenstern, Frank Bruchertseifer, Jeffrey P. Norenberg, Fred J. Verzijlbergen, Marion de Jong and Wouter A. P. Breeman
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:9

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  4. Recently, 44Sc (T1/2 = 3.97 h, Eβ+ av = 632 keV, I = 94.3 %) has emerged as an attractive radiometal candidate for PET imaging using DOTA-functionalized biomolecules. The aim of this study was...

    Authors: Katharina A. Domnanich, Cristina Müller, Renata Farkas, Raffaella M. Schmid, Bernard Ponsard, Roger Schibli, Andreas Türler and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:8

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  5. 6-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (FDOPA) is a frequently used radiopharmaceutical for detecting neuroendocrine and brain tumors and for the differential diagnosis of Parkinson’s disease. To meet the dem...

    Authors: G. Luurtsema, H. H. Boersma, M. Schepers, A. M. T. de Vries, B. Maas, R. Zijlma, E. F. J. de Vries and P. H. Elsinga
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:7

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  6. Typically, metal-based radiopharmaceuticals are synthesized in aqueous solutions with no or low ethanol content. Labeling yields are defined by temperature, period of labeling, amount of precursor, pH etc. As ...

    Authors: Elisabeth Eppard, Marylaine Pèrez-Malo and Frank Rösch
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:6

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  7. 149Tb represents a powerful alternative to currently used α-emitters: the relatively short half-life (T1/2 = 4.1 h), low α-energy (3.97 MeV, Iα = 16.7 %), absence of α-emitting daughters and stab...

    Authors: Cristina Müller, Christiaan Vermeulen, Ulli Köster, Karl Johnston, Andreas Türler, Roger Schibli and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:5

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  8. The widespread acceptance and application of 68Ga-PET depends on our ability to develop radiopharmaceuticals that can be prepared in a convenient and suitable manner. A kit-type labelling protocol provides such c...

    Authors: Johanna Seemann, Bradley Waldron, David Parker and Frank Roesch
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:4

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  9. Phosphodiesterase 10A (PDE10A) is an important regulator of nigrostriatal dopamine (DA) neurotransmission. However, little is known on the effect of alterations in DA neurotransmission on PDE10A availability. ...

    Authors: Maarten Ooms, Sofie Celen, Ronald De Hoogt, Ilse Lenaerts, Johnny Liebregts, Greet Vanhoof, Xavier Langlois, Andrey Postnov, Michel Koole, Alfons Verbruggen, Koen Van Laere and Guy Bormans
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:3

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  10. This is a position paper of the Radiopharmacy Committee of the EANM (European Association of Nuclear Medicine) addressing toxicology studies for application of new diagnostic and therapeutic radiopharmaceutica...

    Authors: J. Koziorowski, M. Behe, C. Decristoforo, J. Ballinger, P. Elsinga, V. Ferrari, P. Kolenc Peitl, S. Todde and T. L. Mindt
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:1

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

Affiliated with